Ebola virus infection is associated with the release of a soluble glycoprotein (sGP) from infected cells. The sGP has been proposed to modulate Ebola virus pathogenesis in primates but little is known about the role of this protein during infection and disease manifestation. So far sGP has been shown to revert the effect of tumor necrosis factor a (TNF-a) on endothelial permeability, indicating that the function of sGP might be antiinflammatory. Since bystander apoptosis of lymphocytes has been demonstrated in Ebola virus infections, we aimed to investigate the ability of sGP to modulate lymphocyte apoptosis and adhesion of lymphocytes to activated endothelium. Recombinant sGP alone or together with TNF-a and the death receptors TRAIL and FAS neither increased nor decreased apoptosis of Jurkat cells, a well-established human lymphocytic cell line. In addition, Jurkat cell adhesion to native or activated human umbilical vein endothelial cells was also found to be not altered by sGP.
In 1976, Ebola virus (EBOV), a member of the family Filoviridae, emerged as the causative pathogen for one of the most severe forms of viral hemorrhagic fever (VHF) in humans and nonhuman primates. To date, there have been 2000 reported cases worldwide with resulting case-fatality rates of 60%-90% depending on the virus species [1] [2] [3] [4] . Cells primary infected by EBOV are monocytes/macrophages and dendritic cells, in which the virus lytically replicates [5, 6] . Virus spread is thought to occur by trafficking of these infected target cells to a wide variety of organs. The release of proinflammatory cytokines and chemokines results in fever, vascular instability, hypotension and shock, and ultimately multiorgan failure [1, 3, 7, 8] . In principle, the endothelium can be affected by EBOV in 2 ways: indirectly by virus-encoded or host-derived factors that cause endothelial activation and dysfunction, and/or directly by virus infection and replication in endothelial cells [8] .
EBOV particles are enveloped and comprise a negativestranded, nonsegmented RNA genome. Gene 4 of the linear genome encodes for several distinct glycoproteins. The primary product of this gene is the precursor of the soluble nonstructural glycoprotein (pre-sGP), which through posttranslational furin cleavage matures into sGP and delta peptide (D-peptide). Both proteins are secreted from infected cells, and sGP has been detected in serum of infected individuals [9, 10] . Expression of the precursor of the structural type I transmembrane glycoprotein (pre-GP) requires messenger RNA (mRNA) editing [9, 11] . This precursor is also posttranslationally cleaved by furin into the disulfide-linked fragments GP 1 and GP 2 [12, 13] , which form homotrimeric GP 1,2 spikes on the surface of the virion that are essential for virus entry [14, 15] .
Until now, no definite function has been associated with sGP, but a role in EBOV pathogenesis has been postulated. The relative abundance of circulating sGP [9] and the finding that noninfected B and T cells undergo high levels of bystander apoptosis during EBOV infection by a hitherto unknown mechanism [16, 17] raises the possibility of an interaction between sGP and these important immune cells. Taken together, these data allowed us to hypothesize that sGP may influence the induction of apoptosis in lymphocytes, as well as their adherence to the vascular endothelium during inflammation, a critical initial step in the host immune response. This hypothesis was supported by our previous studies, where we found that sGP did restore the barrier function of human umbilical vein endothelial cells (HUVECs) following tumor necros factor a (TNFa)-induced permeability [18] . Here we show that neither sGP itself, nor in combination with activation of death receptors, affects lymphocyte apoptosis or lymphocyte adhesion to the activated endothelium.
MATERIALS AND METHODS

Cell Culture
Jurkat cells, a human T cell leukemia cell line [19] , were grown in RPMI medium supplemented with 10% fetal calf serum (FCS), penicillin (100U/mL), streptomycin (100lg/mL) and L-glutamine (2 mmol/L). Human umbilical vein endothelial cells (HUVECs) were isolated from human umbilical cords (approved by the local ethics committee) and cultured with endothelial growth medium (Promocell) as described elsewhere [20] . HUVECs were passaged once and grown to confluence in 24-well-culture plates coated with cross-linked gelatine. All cells were cultured and maintained at 37°C in a 5% CO 2 environment.
Production and Purification of Recombinant Ebola sGP
Recombinant sGP was generated through transfection of 293T cells with a plasmid encoding sGP derived from Zaire ebolavirus (strain Mayinga) with subsequent purification as described elsewhere [21] . Briefly, sGP was tagged with an influenza virus hemagglutinin epitope (HA), allowing immune affinity purification using an anti-HA matrix (Roche). After several steps of concentration, the protein was quantitated, aliquoted, and stored at 280°C. The presence of sGP was determined by western blot analysis using GP-specific monoclonal antibodies (kindly provided by Ayato Takada, Hokkaido University, Sapporo, Japan).
Jurkat Cell Stimulation and Apoptosis Assay
Jurkat cells were transferred into 24 well-culture-plates with a density of 10 6 cells per well in 250 lL of RPMI medium supplemented as described above. sGP was added to the culture medium at a final concentration of 50 lg/mL. Cells were incubated at 37°C for 6, 12, 24, 36, or 48 hours in a 5% CO 2 environment. In a second part of the study, cells were stimulated with apoptosis-inducing mediators including Fasligand (FasL) (10 ng/mL), tumor necrosis factor related apoptosis inducing ligand (TRAIL) (1 ng/mL) and TNF-a (100 ng/mL) (concentrations are known to induce apoptosis [22] ) alone or in combination with sGP (50 lg/mL) under the same conditions. Stimulation and harvesting of the cells was followed by detection and quantification of apoptosis using the Annexin-V-FLUOS Staining Kit following the manufacturer's instructions (Roche). Briefly, Annexin V, here labeled with fluorescein, binds to phosphatidylserine which is exposed in apoptotic cells [23] . Simultaneous labeling with propidium iodide, a DNA stain, allows the identification of necrotic cells, which can be separated from apoptotic cells that become positive for Annexin V. Staining was followed by fluorescence-activated cell scanning (FACS) analysis. The collected data were analyzed using the Cell Quest Software as per instructions from the manufacturer (Becton Dickinson).
Endothelial Cell Activation and Static Adhesion Assay
Pretreatment of HUVECs. Confluent HUVECs cultured in 24-well-culture plates were pretreated with TNF-a (10 ng/mL) for 6 hours. To determine the influence of sGP on HUVEC activation and subsequent T cell adhesion under costimulation with TNF-a, we used either 4 or 40 lg/mL sGP to determine a potential dose-dependent effect. To measure the influence of sGP alone, HUVECs were treated with sGP (40 lg/mL) in the absence of TNF-a. Treatment with recombinant HA peptide in same molarities served as a control.
Adhesion Assay. Jurkat cells were labeled with Cell Tracker Green 5-chloromethylfluorescein diacetate (CMFDA) according to the manufacturer's instructions (Invitrogen) 24 hours before performing the adhesion assays. Jurkat cells were added to the activated endothelium for 30 minutes. To determine the influence of sGP during the process of lymphocyte adhesion, one group of TNF-a-activated HUVECs was incubated with labeled Jurkat cells and 40 lg/mL sGP. Cells were washed with PBS containing 1% FCS 2 times, fixed with 2% paraformaldehyde for 10 minutes, and washed 3 times; cover slips were then mounted with propylgallate for microscopy. Jurkat adhesion was determined by counting 5 randomly selected fields of 1200 lm 3 900 lm each. Images were acquired with a Zeiss Axiovert 100 (Carl Zeiss MicroImaging) equipped with a standard FITC band pass filter Zeiss No. 10 (EX 450-490 nm, BS 510 nm). Acquisition control was performed under the usage of MetaVue (Molecular Devices) software. Adherent cells were counted semiautomatically with ImageJ (Rasband, W.S., ImageJ, U. S. National Institutes of Health, Bethesda, Maryland, USA, http:// rsb.info.nih.gov/ij/, 1997-2009) using appropriate threshold settings, segmentation, and watershed filtering.
Statistical Analyzes
Statistical analyzes were performed by paired t test and analysis of variance (costimulatory effect of sGP on death receptor 
RESULTS AND DISCUSSION
Effect of Recombinant sGP on Jurkat Cell Apoptosis
It has been postulated that sGP plays a role for EBOV pathogenesis and may modulate virus-induced cell death and immune responses [3, 4, 18, 24] . Like in a variety of other infections, lymphocytes have been reported to undergo bystander apoptosis during EBOV infection by an unknown mechanism [3, 4] . Previous data suggest that both the extrinsic and intrinsic apoptotic pathways are involved in this process [25] [26] [27] . To address this question, we aimed to analyze the effect of sGP on Jurkat cell apoptosis. We used the well-established Jurkat lymphocyte cell line [19] to avoid problems arising from heterogeneity of purified lymphocytes from human donors. We purified sGP and its function was verified by its ability to reduce TNF-a-induced decreases in permeability of HUVEC monolayers as described elsewhere [18, 28, 29] . First we tested whether recombinant sGP was able to induce apoptosis of lymphocytes in vitro. Jurkat cells were incubated with sGP at a concentration of 50 lg/mL for 6, 12, 24, 36, and 48 hours. As a negative control, cells were treated with hemagglutinin (HA) peptide at the same molar concentration. The rate of cells undergoing apoptosis was determined by FACS analysis after staining with FITC labeled Annexin V as an indicator of cell apoptosis, and propidium iodide (PI) as an indicator for nonapoptotic cell death ( Figure 1A ). Apoptotic cells were defined as Annexin V-positive but PI-negative cells [23] . Cycloheximide (CHX), which is known to induce apoptosis (control) [30] , was able to induce apoptosis that was already detectable after 6 hours ( Figure 1B) , whereas sGP had no significant effect on Jurkat cell apoptosis (P . .05). These data indicate that recombinant sGP by itself is not able to induce apoptosis, even at concentrations as high as 50 lg/mL and over a period of 48 hours.
Costimulatory Effect of Recombinant sGP on Death Receptor Induced Apoptosis
More recently it was reported that lymphocyte apoptosis in human EBOV infection might be mediated by Fas/FasL interactions [31] . This is in agreement with previous in vitro studies showing up-regulation of TRAIL and Fas/FasL proteins and a down-regulation of bcl-2 under EBOV infection [26, 27] . Apoptosis can be induced by multiple factors including growth factor depletion, virus infections, irreparable internal damage, or conflicting signals targeting the cell cycle. In addition, apoptosis can be induced by activation of so-called death receptors that initiate the cell death program (extrinsic pathway). Recent studies on lymphocyte apoptosis during EBOV infection suggested that both intrinsic and extrinsic pathways are involved in this process [25] . Thus, we investigated whether sGP might accelerate the death receptor-induced cell death program. Jurkat cells were stimulated with the known death receptors TRAIL (1 ng/mL), FasL (10 ng/mL), or TNF-a (100 ng/mL) [22] by any of the 3 agents. Application of cycloheximide induced apoptosis to a maximum level of 45% within 6 hours and served as a positive control. These data indicate that sGP does not modulate apoptosis via the extrinsic (death receptor) pathways. Thus, there is neither evidence for a role of sGP alone in the induction of lymphocyte apoptosis nor in synergism with death receptor treatment.
Effect of Recombinant sGP on Jurkat Cell Adhesion
Interaction of lymphocytes with the vascular endothelium requires both activation of the endothelium and signaling within lymphocytes. Interaction of lymphocytes with the activated endothelium (eg, by cytokines) is initiated by selectin-ligands present on lymphocytes with selectins on activated endothelium [32] . Stronger adhesion requires interaction of integrins with cell adhesion molecules at the activated endothelium, such as the intercellular adhesion molecule 1 (ICAM-1) [32] . Since TNF-a-induced breakdown in barrier function can be partially recovered by sGP [18, 29] , we aimed to investigate whether sGP might modulate the interaction of lymphocytes (Jurkat cells) with activated HUVECs. Confluent HUVEC cultures were pre-stimulated with TNF-a (10 ng/mL) in the absence or presence of recombinant sGP at concentrations of 4 or 40 lg/mL for 6 hours. Subsequently, Jurkat cells were added to the activated endothelial cells. One group of TNF-a-activated HUVEC was incubated with 40 lg/mL sGP during co-culturing with Jurkat cells. Unstimulated HUVECs did not allow adhesion, whereas TNF-a stimulation resulted in firm adhesion of Jurkat cells to HUVEC (Figure 3 ). There was no significant difference in adhesion to activated or nonactivated HUVEC in the absence or presence of sGP. These experiments further demonstrate that sGP has no impact on lymphocyte adhesion to endothelial cells.
In conclusion, data presented here do not support a direct role of sGP in the induction of lymphocyte apoptosis, nor does sGP have an effect on lymphocyte apoptosis induced by known death receptors. This finding is supported by data on Marburg virus, a related filovirus, which also induces lymphocyte apoptosis but does not express the soluble glycoprotein sGP [33] . It is further supported by the fact that lymphocyte apoptosis is not only associated with virus but also bacterial infections and patients with septic shock [34] [35] [36] . However, mechanisms leading to massive lymphocyte apoptosis during infection still remain unclear and may vary between pathogens and hosts. Furthermore, our data do not support any role of sGP on lymphocyte adhesion to the vascular endothelium. This is supported by previous data demonstrating that endothelial activation is mediated by the transmembrane protein GP 1,2 in the context of virus particles and not by the soluble glycoproteins [21] .
Thus, the definite role of sGP in EBOV infection and disease manifestation in primates remains unknown. Here, we examined possible interactions of sGP with lymphocyte adhesion to the endothelium and the extrinsic apoptotic pathway as previous data suggested an involvement of the tumor necrosis factor receptor superfamily in T-cell apoptosis during EBOV infection [26, 27] . Future studies need to address the possibility of an interaction with the intrinsic pathway. The conservation of sGP as the primary expression product of gene 4 of all EBOV species [4] strongly argues for an important function of this protein during EBOV infection in primates. Alternatively, the role of sGP may be associated with EBOV replication in its natural reservoir species. HUVECs were seeded to confluence in 24-well-culture-plates and subsequently exposed to sGP or HA peptide in the presence or absence of TNF-a for 6 h. Jurkat cells were added and allowed to adhere for 30 minutes. To determine the influence of sGP during the process of lymphocyte adhesion to HUVEC, one group of TNF-a-activated HUVEC was incubated with 40 lg/mL sGP during coculturing with Jurkat cells. Data are normalized to adhesion after single TNF-a-activation and shown as means 6 standard errors. Statistical analysis was performed using the paired t test; values were considered to be statistically significant when P , .05. Stimulation with sGP in the absence of TNF-a did not result in HUVEC activation and subsequent Jurkat cell adhesion. Costimulation of HUVEC with sGP 1 TNF-a did not significantly reduce or enhance the number of adherent Jurkat cells. Finally, the addition of sGP during HUVEC/Jurkat co-culturing did not alter the adhesion rate. 
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